Momenta Pharmaceuticals is a biotechnology company focused on the discovery and development of biologic therapies for the treatment of rare immune-mediated diseases. Co.'s programs include: M281, a fully-human anti-neonatal Fc receptor, aglycosylated immunoglobulin G (IgG1), monoclonal antibody; M254, a hyper-sialylated immunoglobulin; M230, a novel recombinant trivalent human IgG1 Fc multimer; and M710, a biosimilar of EYLEA, a vascular endothelial growth factor inhibitor indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema (DME), and Diabetic Retinopathy in patients with DME. We show 46 historical shares outstanding datapoints in our coverage of MNTA's shares outstanding history.
Understanding the changing numbers of MNTA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MNTA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MNTA by allowing them to research MNTA shares outstanding history
as well as any other stock in our coverage universe. |
Free MNTA Email Alerts:
Video: Shares Outstanding Importance
